Trotabresib
CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors[1][2].
Product Specifications
CAS Number
[1706738-98-8]
Product Name Alternative
CC-90010
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cc-90010.html
Concentration
10mM
Purity
99.74
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N(C)C=C(C2=CC(S(=O)(C)=O)=CC=C2OCC3CC3)C4=C1C=CC=C4
Molecular Formula
C21H21NO4S
Molecular Weight
383.46
References & Citations
[1]CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.|[2]V. Moreno, et al. CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study.|[3]Holliday H, et al. Chromatin remodeling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma[J]. bioRxiv, 2024: 2024.06. 06.597703.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
